Vir Biotechnology (VIR) Gross Margin (2020 - 2025)

Vir Biotechnology has disclosed Gross Margin across 6 years of filings, most recently posting 99.09% for Q2 2025.

• Gross Margin for Q2 2025 came in at 99.09%, up 78.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 96.08% (down 264.0% YoY), and the FY2025 annual result was 99.96%, up 110.0% from the prior year.
• Gross Margin came in at 99.09% for Q2 2025 at Vir Biotechnology, down from 100.0% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2021 to a low of 31.28% in Q2 2022.
• The 5-year median for Gross Margin is 97.44% (2024), against an average of 92.81%.
• Across the five-year window, Gross Margin tumbled 6804 bps in 2022 and jumped 6814 bps in 2023, its largest moves.
• Vir Biotechnology's Gross Margin stood at 93.0% in 2021, then slipped by 6 bps to 87.86% in 2022, then gained by 8 bps to 95.25% in 2023, then retreated by 1 bps to 94.47% in 2024, then gained by 5 bps to 99.09% in 2025.
• The last three Gross Margin figures came in at 99.09% (Q2 2025), 100.0% (Q1 2025), and 94.47% (Q4 2024), per Business Quant data.